Non-pharmacological interventions, particularly physical activity and cognitive rehabilitation, are first-line management for cancer-related cognitive impairment in adult cancer survivors
This clinical practice review found that non-pharmacological interventions are recommended as first-line management for cancer-related cognitive impairment (CRCI), with physical activity and cognitive rehabilitation showing the strongest benefits. CRCI affects approximately 60-75% of individuals with cancer and is multifactorial, involving biological and psychosocial contributors.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Non-pharmacological interventions, particularly physical activity and cognitive rehabilitation, are first-line management for cancer-related cognitive impairment in adult cancer survivors The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Non-pharmacological interventions, particularly physical activity and cognitive rehabilitation, are first-line management for cancer-related cognitive impairment in adult cancer survivors
This conclusion is most relevant to: Adult cancer survivors with cancer-related cognitive impairment.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Cancer-related cognitive impairment in adult cancer survivors: a clinical practice review for healthcare providers. (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026) —
How It Works
The proposed biological pathway:
- ▸Cancer and its treatments (chemotherapy, endocrine therapy, radiotherapy, surgery) induce neuroinflammation, oxidative stress, neurotoxicity, and hormonal dysregulation
- ▸Psychological distress, anxiety, depression, and fatigue contribute to cognitive decline
- ▸Non-pharmacological interventions such as physical activity and cognitive rehabilitation target these mechanisms by reducing inflammation, improving neuroplasticity, and addressing psychosocial factors
- ▸Result: Improved cognitive outcomes and functional status in cancer survivors
Who Might Benefit
Evidence fit by population:
- ▸Adult cancer survivors with cancer-related cognitive impairment
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Narrative review, not a systematic review or meta-analysis, so evidence synthesis may be less rigorous
- ▸Specific effect sizes and comparative efficacy of individual interventions are not quantified in the abstract
- ▸Pharmacological therapies showed inconsistent results, but the review does not detail which agents were evaluated or their outcomes
Frequently Asked Questions
What is cancer-related cognitive impairment (CRCI)?▼
CRCI is a decline in cognitive function associated with cancer and its treatments, affecting approximately 60-75% of individuals with cancer. It includes problems with memory, attention, and executive function.
What are the first-line treatments for CRCI?▼
Non-pharmacological interventions are first-line, with physical activity and cognitive rehabilitation showing the strongest benefits. Mindfulness-based interventions, psychoeducation, and lifestyle modifications may also help.
Are there any medications recommended for CRCI?▼
Pharmacological therapies, including psychostimulants and neuroprotective agents, have shown inconsistent results and are not routinely recommended.
How is CRCI assessed?▼
Assessment should include both patient-reported cognitive concerns and objective neuropsychological testing, while also evaluating potentially reversible contributors such as sleep disturbances, pain, medication effects, and emotional distress.
References
- 1.Bhinder JK, Peera M, Kennedy SKF, Hart NH, Haywood D, Al-Khaifi M. “Cancer-related cognitive impairment in adult cancer survivors: a clinical practice review for healthcare providers..” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. PMID: 42616177 DOI: 10.1007/s00520-026-11092-0